+353 (0) 1 296 8675 ISIC20@conferencepartners.ie

Keynote Speakers

Prof Mike Zaworotko

Bernal Chair of Crystal Engineering

University Of Limerick


Monday 4th September, 8:40 – 9:20,  Crystal engineering: from form to function

Dr. Mike Zaworotko currently serves as Bernal Chair of Crystal Engineering & Science Foundation of Ireland Research Professor at the University of Limerick, Ireland. He was born in Wales in 1956 and received his B.Sc. and Ph.D. degrees from Imperial College (1977) and the University of Alabama (1982), respectively.
Research activities have focused on fundamental and applied aspects of crystal engineering since 1990. Currently, metal-organic materials (MOMs), especially microporous and ultra-microporous physisorbents, and multi-component pharmaceutical materials (MPMs) such as cocrystals, hydrates, and ionic co-crystals are of particular interest.”

Prof Richard Sear

Department of Physics

University of Surrey

United Kingdom

Monday 4th September, 15:00 – 15:40, Controlling the polymorph that crystallises by exploiting the opposite time dependencies of the competing nucleation rates

I am a computational physicist working mainly crystallisation, but also in other areas of soft matter physics. My group also undertakes quantitative experiments on crystal nucleation. I am interested in the fundamentals of how crystals nucleate and grow, and have studied crystallising systems from proteins to small molecules to ice. Typical techniques are computer simulation to look at the microscopic mechanism of nucleation, and statistical models to model quantitatively the experimental phenomenology of crystallisation. I also study ‘paint drying’, i.e., the non-equilibrium physics of self-organisation in a colloidal suspension where the liquid is evaporating. My PhD (1995) was from Sheffield, and after postdocs at AMOLF in Amsterdam and at the University of California Los Angeles, I have been at the University of Surrey since 1998.

Prof Cristobal Viedma

Professor of Crystallography and Mineralogy

Madrid University


Tuesday 5th September, 9:20 – 10:00, Symmetry Breaking in chiral crystallization: Pharmaceuticals and the origin of life

“Cristobal Viedma was born in Andalusia, Spain. He received his M.S. degree in Geology at the University Complutense of Madrid and obtained his PhD working on mass transfer and crystallization in gels. He is now Professor of Crystallography and Mineralogy at the University of Madrid.
His research specialization is in the broad field of crystallization with a special interest in crystallization of minerals, proteins, chiral crystallization and in the relationship between crystallography and problems with the origin of life as biochirality or prebiotic peptides formation.
Recently he discovered a physicochemical phenomenon by which an initially racemic mixture of crystals transforms into an end state in which all the crystals are of one chiral form. This transformation is now called “”Viedma ripening””.”

Dr. Susan M. Reutzel-Edens

Sr. Research Advisor

Eli Lilly And Company

United States

Tuesday 5th September, 16:20 – 17:00,  Painting a molecular picture of polymorph crystallization

Susan M. Reutzel-Edens is a Senior Research Advisor in Small Molecule Design & Development at Eli Lilly and Company. She obtained her B.S. degree in chemistry from Winona State University, then earned her Ph.D. in organic chemistry at the University of Minnesota. Upon joining Eli Lilly, she developed Lilly’s solid form design program and for two decades led a team of cross-functional scientists charged with finding commercially-viable crystalline forms for small-molecule drug products. Her research interests include crystal polymorphism, crystallization, structure-property relationships, crystal structure prediction as a complement to experimental solid-state form screening and digital drug product design.

Dr. Philip Dell’Orco

VP, Advanced Manufacturing Technologies


United States

Wednesday 6th September, 11:30 – 12:10, The quest for a platform particle

Dr Philip Dell’Orco, VP, Advanced Manufacturing Technologies in GlaxoSmithKline, works across R&D and global manufacturing to transform drug manufacturing processes.  Prior to his current role, Phil held several global department head roles within GSK R&D, with accountabilities spanning device design and industrialization, process engineering for drug substance and drug product processes, process modelling, drug substance crystallization, and drug developability.  Previous roles include director of engineering in R&D pilot plants, and as a process safety practitioner/manager.  Prior to GSK, Phil worked at Los Alamos National Lab as a Technical Staff Member in the Dynamic Experimentation group.